Catalogue Number
BD-D1261
Analysis Method
HPLC,NMR,MS
Specification
98%(HPLC)
Storage
2-8°C
Molecular Weight
374.34
Appearance
Powder
Botanical Source
Structure Type
Monoterpenoids
Category
SMILES
C=C1C(CC2C1C(OC=C2C(=O)O)OC3C(C(C(C(O3)CO)O)O)O)O
Synonyms
(1S,4aS,6S,7aS)-6-hydroxy-7-methylidene-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,5,6,7a-tetrahydro-1H-cyclopenta[c]pyran-4-carboxylic acid
IUPAC Name
(1S,4aS,6S,7aS)-6-hydroxy-7-methylidene-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,5,6,7a-tetrahydro-1H-cyclopenta[c]pyran-4-carboxylic acid
Density
Solubility
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Flash Point
Boiling Point
Melting Point
InChl
InChI=1S/C16H22O10/c1-5-8(18)2-6-7(14(22)23)4-24-15(10(5)6)26-16-13(21)12(20)11(19)9(3-17)25-16/h4,6,8-13,15-21H,1-3H2,(H,22,23)/t6-,8+,9-,10-,11-,12+,13-,15+,16+/m1/s1
InChl Key
JSKCJJNYSGWZDU-RQJSCMEKSA-N
WGK Germany
RID/ADR
HS Code Reference
2933990000
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:54835-76-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
24427090
Refluxing a mixture of 1,10-phenanthroline, (4-fluorophenyl)thiourea and cadmium(II) chloride did not produce the expected mixed-ligand complex but formed a co-crystal of the two ligands, C12H8N2·C7H7FN2S. The asymmetric unit consists of two pairs of the co-crystal molecules. In each (4-fluorophenyl)thiourea molecule, the planes of the N2CS thiourea units are almost perpendicular to the corresponding fluorobenzene rings, subtending angles of 76.53 (7) and 85.25 (7)°. In the crystal, N—H⋯N and N—H⋯S hydrogen bonds form inversion dimers from the co-crystal pairs. A weak π-π interaction between the phenanthroline rings [centroid-centroid distance = 3.7430 (15)a] is also observed.
(4-Fluorophenyl)thiourea-1,10-phenanthroline (1/1)
Bohari M. Yamin,a Halima F. Salem,a and Siti Fairus M. Yusoffa,*
2013 Sep 1;
26517707
RNA editing is the post-transcriptional conversion from C to U before translation, providing a unique feature in the regulation of gene expression. Here, we used a robust and efficient method based on RNA-seq from non-ribosomal total RNA to simultaneously measure chloroplast-gene expression and RNA editing efficiency in the Greater Duckweed, Spirodela polyrhiza, a species that provides a new reference for the phylogenetic studies of monocotyledonous plants. We identified 66 editing sites at the genome-wide level, with an average editing efficiency of 76%. We found that the expression levels of chloroplast genes were relatively constant, but 11 RNA editing sites show significant changes in editing efficiency, when fronds turn into turions. Thus, RNA editing efficiency contributes more to the yield of translatable transcripts than steady state mRNA levels. Comparison of RNA editing sites in coconut, Spirodela, maize, and rice suggests that RNA editing originated from a common ancestor.
RNA Editing in Chloroplasts of Spirodela polyrhiza, an Aquatic Monocotelydonous Species
Wenqin Wang, Wei Zhang, Yongrui Wu, ¤ Pal Maliga, and Joachim Messing*
2015;
19821293
Background
Dysmenorrhoea (painful menstrual cramps) is common. Combined OCPs are recommended in the management of primary dysmenorrhoea.
Objectives
To determine the effectiveness and safety of combined oral contraceptive pills for the management of primary dysmenorrhoea.
Search methods
We conducted electronic searches for randomised controlled trials (RCTs) in the Cochrane Menstrual Disorders and Subfertility Group Register of controlled trials CENTRAL, CCTR, MEDLINE, EMBASE, and CINAHL (first conducted in 2001, updated on 5 November 2008).
Selection criteria
RCTs comparing all combined OCPs with other combined OCPs, placebo, no management, or management with nonsteroidal anti‐inflammatories (NSAIDs) were considered.
Data collection and analysis
Twenty three studies were identified and ten were included. Six compared the combined OCP with placebo and four compared different dosages of combined OCP.
Main results
One study of low dose oestrogen and four studies of medium dose oestrogen combined OCPs compared with placebo, for a combined total of 497 women, reported pain improvement. For the outcome of pain relief across the different OCPs the pooled OR suggested benefit with OCPs compared to placebo (7 RCTs: Peto OR 2.01 [95% CI 1.32, 3.08]).The Chi‐squared test for heterogeneity showed there is significant heterogeneity with an I2 statistic of 64% and a significant chi‐square test (14.06, df=5, p=0.02). A sensitivity analysis removing the studies with inadequate allocation concealment suggested significant benefit of treatment with the pooled OR of 2.99 (95% CI 1.76, 5.07) and heterogeneity no longer statistically significant and I2 statistic of 0%.
Three studies reported adverse effects (Davis 2005; Hendrix 2002; GPRG 1968) The adverse effects were nausea, headaches and weight gain. Two studies reported if women experienced any side effect and no evidence of an effect was found (3 RCTs: OR = 1.45 (95% 0.71, 2.94). There was no evidence of statistical heterogeneity.
There were no studies identified that compared combined OCP versus non steroidal anti‐inflammatory drugs
There was no evidence of a difference for the pooled studies for 3rd generation pro gestagens (OR = 1.11 (95% CI 0.79 ‐ 1.57)). For the 2nd generation versus 3rd generation the OR was 0.44 (95% CI 0.23‐0.84) suggesting benefit of the 3rd generation OCP but this was for a single study (Winkler 2003).
Authors’ conclusions
There is limited evidence for pain improvement with the use of the OCP (both low and medium dose oestrogen) in women with dysmenorrhoea. There is no evidence of a difference between different OCP preparations.
Oral contraceptive pill for primary dysmenorrhoea
Monitoring Editor: Chooi L Wong,corresponding author Cindy Farquhar, Helen Roberts, Michelle Proctor, and Cochrane Gynaecology and Fertility Group
2009 Oct